Marin Biologic Laboratories Releases FDA-Ready Bioanalytical Cell-Based Assays White Paper
'Whether you're preparing for your first IND or scaling up for commercial release, assay integrity is non-negotiable. This white paper reflects our commitment to excellence.'— Tania Weiss, Ph.D., CEO, Marin Biologic Laboratories
NOVATO, CA, UNITED STATES, June 27, 2025 / EINPresswire.com / -- Marin Biologic Laboratories Inc. (MarinBio), a leading bioanalytical testing and regulatory compliance contract research organization (CRO) based in Northern California, announces the release of a new white paper, 'Selecting Bioanalytical Assays for FDA Approved Clinical Trials and Commercialization.' https://www.marinbio.com/ company/selecting-bioanalytical-assays-fda-clinical-trials-commercialization/
This in-depth publication offers the biopharmaceutical industry a clear, scientifically grounded roadmap for selecting regulatory-ready assays that meet FDA requirements. The white paper walks readers through the full continuum of assay development—from early-stage, fit-for-purpose qualified assays to fully validated, GMP-compliant platforms ready for BLA and NDA submission, and commercialization.
'Whether you're preparing for your first IND or scaling up for commercial release, assay integrity is non-negotiable,' said Tania Weiss, Ph.D., CEO of Marin Biologic Laboratories. 'This white paper reflects our commitment to excellence—scientific, operational, and regulatory—and our desire to enable clients to meet FDA expectations without unnecessary delays or cost overruns. Our goal has always been to act as a true scientific partner to our clients, including those pioneering the next generation of therapeutics. This white paper is a natural extension of that mission. We are codifying three decades of experience to provide the entire industry with a clear, actionable framework for navigating the immense complexities of modern drug development. We believe that sharing our expertise in regulatory strategy and advanced bioanalysis will help accelerate innovation across the board.'
The white paper content leverages MarinBio's 30 years of scientific leadership and impeccable regulatory track record to enable companies on their journey from preclinical projects to commercialization. The publication draws upon MarinBio's deep expertise in GMP/GLP-compliant assay development and its recent successes in passing both FDA, with no 483s, and EU regulatory audits.
Key insights from the white paper include:
- Phase 1: Research-Level Assay Development – Streamlined approaches for initial technology transfer or de novo assay design that deliver reliable, fit-for-purpose data for preclinical and early clinical studies.
- Phase 2: Assay Qualification – Criteria for building a qualified assay for Phase 2 FDA submissions including intermediate precision, accuracy, linearity, and specificity to support IND-enabling studies with confidence.
- Phase 3 & Commercial: GMP Assay Validation – A guideline for validating, and documenting robust assays in full compliance with GLP/GMP and FDA standards—ready for commercial deployment.
The white paper also offers real-world advice for biotech and pharma clients navigating pre-IND/IND readiness and BLA/NDA submissions and commercialization phase —making it an essential read for development teams, regulatory leads, and scientific executives.
About Marin Biologic Laboratories Inc.
Marin Biologic Laboratories (MarinBio) is a woman-owned contract research organization (CRO) with over 30 years of experience supporting the pharmaceutical and biotech sectors. Specializing in custom cell-based assays, GMP/GLP compliance, and regulatory strategy, MarinBio partners with clients to advance therapeutics from discovery to commercialization. With a team of senior PhD scientists and a flawless regulatory audit history, MarinBio provides the scientific expertise and quality systems necessary to meet global compliance standards.
Marin Biologic Laboratories is recognized for its scientific agility, rigorous quality systems, and deep understanding of FDA regulatory expectations. The company is known for working collaboratively with clients, ensuring each assay is customized to meet specific regulatory, technical, and commercial goals.
Operating from a GMP-compliant facility in Novato, CA, MarinBio supports US and international clients ranging from venture-backed startups to top-tier global biopharma firms. The company's service portfolio includes:
- Potency Assays for Lot Release
- Stability Testing
- PK/PD & Immunogenicity Studies (ADA)
- ELISA, Flow Cytometry
- Cell-Based Assays ( https://www.marinbio.com/services/cell-based-assays/ )
- Molecular Biology
- qPCR
- GMP / GLP Compliant Validation and Regulatory Reporting
For the complete white paper or to discuss your bioanalytical assay development needs, please visit the MarinBio website at https://www.marinbio.com/
Tania L. Weiss, Ph.D.
Marin Biologic Laboratories, Inc.
+1 4158838000x100
email us here
Visit us on social media:
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
a few seconds ago
- The Hill
FTC sues LA Fitness operators for ‘exceedingly difficult' gym cancellation policies
NEW YORK (AP) — The U.S. Federal Trade Commission is suing the operators of LA Fitness, over allegations that they make it 'exceedingly difficult' for consumers to cancel gym memberships and other related services offered in their clubs nationwide. In a Wednesday complaint, the FTC accused Fitness International and its subsidiary Fitness & Sports Clubs of illegally charging consumers 'hundreds of millions of dollars in unwanted recurring fees' as a result of cumbersome cancellation processes. The agency said that tens of thousands of customers have reported difficulties with these policies to date. 'The FTC's complaint describes a scenario that too many Americans have experienced — a gym membership that seems impossible to cancel,' Christopher Mufarrige, director of the agency's Bureau of Consumer Protection, said in a statement. Beyond LA Fitness, California-based Fitness International operates brands like Esporta Fitness, City Sports Club, and Club Studio — spanning across more than 600 locations with over 3.7 million members nationwide. And the FTC pointed to two 'unfair and unlawful' cancellation processes that it says these gyms have used for years: in-person cancellation or cancellation by mail. Both of these options require consumers to print out a form on the gym's website, which includes logging in with credentials that the agency says some customers don't have or remember. And if a customer opts for in-person cancellation, there's limited hours and often difficulty finding a manager to process the forms, the complaint notes — while mailing the form comes with additional costs. 'Each of these cancellation methods is opaque, complicated, and demanding — far from simple,' the FTC writes in its complaint. It also alleges that the company doesn't adequately disclose cancellation offerings when consumers sign up for memberships, and that some will be signed up for additional services with recurring charges without realizing there may be different cancellation requirements. According to the FTC, Fitness International now offers website cancellations for subscriptions 'with stand-alone agreements' — but the agency said the process 'still imposes unnecessary burdens' on customers and claims that that option is buried online. It's also still not possible to cancel memberships on the company's mobile apps, the FTC added. Fitness International did not immediately respond to The Associated Press' request for comment on Wednesday. This isn't the first time that federal regulators have accused gym operators — and other companies with subscription services — of making their cancellation processes too difficult for consumers. Under the Biden administration, the FTC adopted a 'click to cancel' rule, which would have made it easier for consumers to end unwanted subscriptions. But last month, days before that rule was poised to go into effect, a federal appeals court blocked the proposed changes. In its litigation against Fitness International, the FTC says it's seeking a court order prohibiting the allegedly unfair conduct and money back for consumers who were harmed by difficult cancellation processes.
CNN
a minute ago
- CNN
AI and tech stocks slide as summer rally peters out
Tech news Investing Stocks AIFacebookTweetLink Follow Tech stocks were under pressure this week as Wall Street's AI enthusiasm slowed and investors adjusted portfolios after a strong summer rally. The Nasdaq Composite fell 0.67% on Wednesday after sliding 1.46% on Tuesday. The tech-heavy index was on track to snap back-to-back weeks of gains. Meanwhile, the broader S&P 500 fell 0.24% and posted its fourth day of losses in a row. The Dow hovered around the flatline. Tech stocks had steadily rallied in recent months, lifting the S&P 500 and Nasdaq to a streak of record highs. Now Wall Street is taking a breather while optimism about the AI boom is facing some friction. Palantir (PLTR), a star of the AI trade, fell 1.1% on Wednesday after falling 9.35% on Tuesday. Meanwhile, Nvidia (NVDA) edged lower by 0.14% on Wednesday after sliding 3.5% on Tuesday. 'Investors rotated out of high-momentum tech stocks, reflecting renewed jitters over the sustainability of the AI trade,' Ulrike Hoffmann-Buchardi, head of global equities at UBS, said in a note. Investors are also in wait-and-see mode ahead of a critical day for markets on Friday when Federal Reserve Chair Jerome Powell is set to deliver remarks at the Jackson Hole Economic Symposium. 'It's just a pause that may refresh as investors retrench and rethink how they want to position their tech dollars,' Rob Haworth, senior investment strategy director at US Bank Asset Management Group, told CNN. Powell's closely watched speech on Friday could provide signals about the Fed's potential rate-cutting path and comes at a key inflection points for markets after past months' ascent to record highs. Excitement about AI propelled markets higher in recent months, boosted by robust corporate earnings and enormous spending by companies like Meta and Microsoft. But Wall Street's eagerness was tested this week after Sam Altman, chief executive at OpenAI, said he thinks the market might be in a bubble. 'Are we in a phase where investors as a whole are overexcited about AI? My opinion is yes,' Altman told reporters last week, according to The Verge. The OpenAI chief also said he thinks AI will provide value for the economy. 'Is AI the most important thing to happen in a very long time? My opinion is also yes,' he said. Also, researchers at MIT on Monday published a report detailing how the majority of companies testing new generative AI tools are seeing zero returns. While there was not an explicit catalyst for the decline of tech and AI stocks decline this week, investors said Altman's comments and the MIT report could be contributing to negative momentum. AI chip and semiconductor companies Advanced Micro Devices (AMD) and Marvell Technology (MRVL) were each down almost 7% this week. 'Altman's comments spooked some people when he talked about the AI bubble,' Dan Ives, head of global technology research at Wedbush Securities, told CNN. 'Tech stocks have had a massive run, so I think it's just typical that investors are starting to take some chips off the table going into Labor Day,' Ives said. 'But I believe it's going to be short lived.' Each of the Magnificent Seven tech stocks — Apple (AAPL), Alphabet (GOOGL), Amazon (AMZN), Meta (META), Microsoft (MSFT), Nvidia (NVDA) and Tesla (TSLA) — fell on both Tuesday and Wednesday, dragging down the broader market. As of Tuesday, they made up 33.5% of the S&P 500's total market value, according to S&P Dow Jones Indices, reflecting their outsized influence on the index's performance. 'Stocks have been on an absolute tear. Valuations have sprinted up,' said Ross Mayfield, an investment strategist at Baird. 'The fundamentals are good but not keeping pace with the price action.' 'I think along the way we'll see pockets of profit taking, even if it doesn't mark the end of the bull market in general,' Mayfield said. While tech dragged on the market, about 70% of stocks in the S&P 500 had closed higher on Tuesday, UBS' Hoffmann-Buchardi said. Sectors that outperformed included consumer staples, utilities and real estate. It's a sign that investors are shifting out of Big Tech and AI-related trades and toward more defensive stocks as they reassess the markets. Nvidia as of Monday had surged 93% since a low point in early April. 'We've been expecting this type of a pullback,' said Jay Hatfield, chief executive at Infrastructure Capital Advisors, who said he has taken down his exposure to tech in recent months. It's also the start of a historically weak season for stocks, Hatfield said. 'We're neutral on the market right now, but still really bullish for year end.' Palantir is still up 106% this year. But shares in Palantir are down six days in a row and had dropped as much as 9.8% on Wednesday before paring losses, reflecting the volatility in AI stocks. 'Now we're getting the downward momentum,' Hatfield said. 'Palantir is like the poster child for excessive valuation, and those investors are learning that the momentum works in both directions.'
2 minutes ago
FTC sues LA Fitness operators for 'exceedingly difficult' gym cancellation policies
NEW YORK -- The U.S. Federal Trade Commission is suing the operators of LA Fitness, over allegations that they make it 'exceedingly difficult' for consumers to cancel gym memberships and other related services offered in their clubs nationwide. In a Wednesday complaint, the FTC accused Fitness International and its subsidiary Fitness & Sports Clubs of illegally charging consumers 'hundreds of millions of dollars in unwanted recurring fees' as a result of cumbersome cancellation processes. The agency said that tens of thousands of customers have reported difficulties with these policies to date. 'The FTC's complaint describes a scenario that too many Americans have experienced — a gym membership that seems impossible to cancel,' Christopher Mufarrige, director of the agency's Bureau of Consumer Protection, said in a statement. Beyond LA Fitness, California-based Fitness International operates brands like Esporta Fitness, City Sports Club, and Club Studio — spanning across more than 600 locations with over 3.7 million members nationwide. And the FTC pointed to two 'unfair and unlawful' cancellation processes that it says these gyms have used for years: in-person cancellation or cancellation by mail. Both of these options require consumers to print out a form on the gym's website, which includes logging in with credentials that the agency says some customers don't have or remember. And if a customer opts for in-person cancellation, there's limited hours and often difficulty finding a manager to process the forms, the complaint notes — while mailing the form comes with additional costs. 'Each of these cancellation methods is opaque, complicated, and demanding — far from simple,' the FTC writes in its complaint. It also alleges that the company doesn't adequately disclose cancellation offerings when consumers sign up for memberships, and that some will be signed up for additional services with recurring charges without realizing there may be different cancellation requirements. According to the FTC, Fitness International now offers website cancellations for subscriptions 'with stand-alone agreements' — but the agency said the process 'still imposes unnecessary burdens' on customers and claims that that option is buried online. It's also still not possible to cancel memberships on the company's mobile apps, the FTC added. Fitness International did not immediately respond to The Associated Press' request for comment on Wednesday. This isn't the first time that federal regulators have accused gym operators — and other companies with subscription services — of making their cancellation processes too difficult for consumers. Under the Biden administration, the FTC adopted a 'click to cancel' rule, which would have made it easier for consumers to end unwanted subscriptions. But last month, days before that rule was poised to go into effect, a federal appeals court blocked the proposed changes.
